Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ABT | COURT-RULING | neutral | 1/10 | The court granted Abbott Laboratories' unopposed administrative motion for excess pages in two consolidated product-liab | Jul 8, 2026 |
| RYTM | PRESS-RELEASE | bullish | 6/10 | Rhythm Pharmaceuticals announced that the Phase 3 TRANSCEND trial results for setmelanotide (IMCIVREE) in acquired hypot | Jul 8, 2026 |
| GRML | 8-K | neutral | 4/10 | Greenland Mines terminated its At-the-Market Sales Agreement with A.G.P./Alliance Global Partners effective July 4, 2026 | Jul 8, 2026 |
| MGNX | 8-K | neutral | 2/10 | Karen Ferrante, M.D. resigned from the board of MacroGenics for personal reasons, effective September 1, 2026. The depar | Jul 8, 2026 |
| OKYO | 6-K | bullish | 7/10 | OKYO Pharma reported positive feedback from an FDA Type D meeting, validating the regulatory and clinical path for urcos | Jul 8, 2026 |
| OVID | 8-K | neutral | 2/10 | Ovid Therapeutics announced the departure of CFO Jeffery Rona by mutual agreement, effective July 6, 2026, with an inter | Jul 8, 2026 |
| MRNA | 8-K | neutral | 2/10 | Moderna appointed Michael McDonnell, former CFO of Biogen, to its Board of Directors effective July 8, 2026. McDonnell w | Jul 8, 2026 |
| BLRX | 6-K | bullish | 5/10 | BioLineRx announced positive preclinical data demonstrating strong synergy between its lead candidate GLIX1 and PARP inh | Jul 8, 2026 |
| AURA | 8-K | neutral | 3/10 | Aura Biosciences appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors as a Class II director, effective Jul | Jul 8, 2026 |
| CMMB | 6-K | bullish | 7/10 | Chemomab Therapeutics (CMMB) entered into a definitive merger agreement to be acquired by Scipher Medicine Corporation, | Jul 8, 2026 |
| MCRB | 8-K | bullish | 7/10 | Seres Therapeutics announced positive top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in | Jul 8, 2026 |
| PRME | 8-K | bullish | 6/10 | Prime Medicine won a binding arbitration against Beam Therapeutics, with the tribunal ruling that Prime's AATD candidate | Jul 8, 2026 |
| PRFX | 6-K | neutral | 3/10 | PRF Technologies announced the successful validation of its DeepSolar Predict AI platform using real-world European mark | Jul 8, 2026 |
| EOLS | 8-K | bullish | 6/10 | Evolus entered into an exclusive license and distribution agreement with IBSA to develop and commercialize Profhilo, a m | Jul 8, 2026 |
| HYPD | 8-K | neutral | 3/10 | Hyperion DeFi entered into new employment agreements with CEO/CIO Hyunsu Jung, CFO David Knox, and General Counsel Rober | Jul 8, 2026 |
| NCEL | 6-K | neutral | 3/10 | NewcelX announced the appointment of Dr. Camillo Ricordi, a world-renowned diabetes researcher, to its Scientific Adviso | Jul 8, 2026 |
| ALKS | 8-K | neutral | 3/10 | Alkermes and Amneal Pharmaceuticals mutually terminated the Authorized Generic Product Supply Agreement for VIVITROL (na | Jul 8, 2026 |
| ZEOX | 8-K | bullish | 5/10 | Zeo ScientifiX reported strong revenue growth of 124.6% for the quarter ended April 30, 2026, reaching $2.58M, up from $ | Jul 8, 2026 |
| PHGE | PRESS-RELEASE | neutral | 4/10 | BiomX announced a non-binding LOI to acquire 60% of Tsoock Defense Technologies for $10.4M, payable mostly in quarterly | Jul 8, 2026 |
| OKYO | PRESS-RELEASE | bullish | 6/10 | OKYO Pharma announced positive FDA Type D meeting feedback validating a single-dose Phase 3 pivotal trial design for urc | Jul 8, 2026 |
| CATX | PRESS-RELEASE | neutral | 2/10 | Perspective Therapeutics announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer, succeeding co-founder | Jul 8, 2026 |
| MSLE | PRESS-RELEASE | bullish | 7/10 | Satellos reported six-month interim data from the TRAILHEAD Phase 2 study of SAT-3247 in adults with Duchenne muscular d | Jul 8, 2026 |
| MSLE | 6-K | bullish | 6/10 | Satellos reported six-month interim TRAILHEAD data showing SAT-3247 reduced muscle fat fraction (mean -3.7%), increased | Jul 8, 2026 |
| JUNS | EFFECT | bearish | 6/10 | The SEC declared effective Jupiter Neurosciences' S-1 registration statement (File No. 333-297073), registering 16,000,0 | Jul 8, 2026 |
| TAK | 6-K | neutral | 2/10 | Takeda completed the issuance of 16.88 million ordinary shares (including treasury shares) at 5,050 yen per share under | Jul 8, 2026 |
| ADXN | 6-K | neutral | 2/10 | Addex Therapeutics announced a preclinical publication on ADX71743, a selective mGlu7 negative allosteric modulator, dem | Jul 8, 2026 |
| TPST | EFFECT | bearish | 5/10 | Tempest Therapeutics' S-3 registration statement (File No. 333-297061) became effective on July 7, 2026, enabling the re | Jul 8, 2026 |
| AKTX | EFFECT | neutral | 4/10 | This is a notice of effectiveness (EFFECT) for a resale shelf (File No. 333-289962) covering up to 2.5 million ADSs that | Jul 8, 2026 |
| AMPH | 8-K | bearish | 6/10 | Amphastar subsidiary IMS received an FDA Warning Letter for CGMP violations at its South El Monte, CA manufacturing faci | Jul 8, 2026 |
| XERS | CLUSTER | bearish | 4/10 | Three Xeris Biopharma insiders (C-suite/top officers) sold a total of ~$1.0M in stock over a 7-day window ending July 6, | Jul 8, 2026 |